Holen Sie sich die Stockscreener-App
44.06
1.78%
0.77
Handel nachbörslich:
43.80
-0.26
-0.59%
Schlusskurs vom Vortag:
$43.29
Offen:
$42.98
24-Stunden-Volumen:
2.37M
Relative Volume:
1.52
Marktkapitalisierung:
$8.14B
Einnahmen:
$29.52M
Nettoeinkommen (Verlust:
$-567.06M
KGV:
-13.52
EPS:
-3.26
Netto-Cashflow:
$-551.11M
1W Leistung:
-2.11%
1M Leistung:
-22.80%
6M Leistung:
+17.37%
1J Leistung:
+71.51%
1-Tages-Spanne:
$42.53
$44.22
1-Wochen-Bereich:
$42.53
$46.15
52-Wochen-Spanne:
$25.91
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
Firmenname
Revolution Medicines Inc
Sektor
Branche
Telefon
415-766-3638
Adresse
700 SAGINAW DR, REDWOOD CITY, CA
Vergleichen Sie RVMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
44.06 | 8.14B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-16 | Bestätigt | Needham | Buy |
| 2024-07-12 | Eingeleitet | Barclays | Overweight |
| 2024-07-08 | Eingeleitet | Jefferies | Buy |
| 2024-04-12 | Bestätigt | Needham | Buy |
| 2024-04-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-04 | Eingeleitet | Wedbush | Outperform |
| 2023-11-16 | Eingeleitet | Raymond James | Outperform |
| 2023-02-28 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-10-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-05-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-03-01 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-08-12 | Herabstufung | Goldman | Buy → Neutral |
| 2021-05-18 | Eingeleitet | Goldman | Buy |
| 2020-05-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-09 | Eingeleitet | Cowen | Outperform |
| 2020-03-09 | Eingeleitet | Guggenheim | Buy |
| 2020-03-09 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
Revolution Medicines CEO Mark Goldsmith sells $531,860 in stock By Investing.com - Investing.com Australia
Break Through Cancer and Revolution Medicines Collaborate to Study Biomarkers for RAS(ON) Inhibitor in - EIN News
Revolution Medicines general counsel sells $72,600 in stock By Investing.com - Investing.com Australia
Revolution Medicines CEO Mark Goldsmith sells $531,860 in stock - Investing.com India
Revolution Medicines COO Margaret Horn sells shares worth $196,553 By Investing.com - Investing.com Canada
Revolution Medicines CFO Jack Anders sells shares worth $119,639 By Investing.com - Investing.com South Africa
Revolution Medicines, Inc. (NASDAQ:RVMD) COO Sells $196,536.60 in Stock - MarketBeat
Revolution Medicines general counsel sells $72,600 in stock - Investing.com
Revolution Medicines CFO Jack Anders sells shares worth $119,639 - Investing.com
Insider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Insider Sells 11,714 Shares of Stock - MarketBeat
Jack Anders Sells 2,635 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) Stock - MarketBeat
Revolution Medicines COO Margaret Horn sells shares worth $196,553 - Investing.com
Finance Watch: FOPO Surge Continues With Big Offerings From Revolution, NewAmsterdam - Citeline News & Insights
(RVMD) Technical Data - Stock Traders Daily
Revolution Medicines' SWOT analysis: RAS inhibitor stock shows promise amid clinical trials - Investing.com
Wilmington Savings Fund Society FSB Invests $801,000 in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Barclays PLC Buys 192,021 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
One Revolution Medicines Insider Raised Their Stake In The Previous Year - Yahoo Finance
State Street Corp Has $239.43 Million Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Verition Fund Management LLC Takes Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines director Schroeder acquires $59.9m in stock By Investing.com - Investing.com Nigeria
Revolution Medicines director Schroeder acquires $59.9m in stock - Investing.com India
Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Brokerages Set Revolution Medicines, Inc. (NASDAQ:RVMD) Price Target at $63.67 - MarketBeat
What is HC Wainwright's Estimate for RVMD FY2024 Earnings? - MarketBeat
How to Take Advantage of moves in (RVMD) - Stock Traders Daily
Revolution Medicines completes $823 million public offering By Investing.com - Investing.com Canada
Revolution Medicines completes $823 million public offering - Investing.com
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewswire
Latham Watkins Advises Revolution Medicines in Upsized US750 Million Public Offering of Common Stock - Latham & Watkins LLP
Revolution Medicines: Risky Buy On Recent Share Price Dip (NASDAQ:RVMD) - Seeking Alpha
Revolution Medicines price target raised to $87 from $82 at Guggenheim - Yahoo Finance
Top 3 Health Care Stocks That Could Blast Off In December - Benzinga
Janus Henderson Group PLC Acquires 1,497,026 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Edgestream Partners L.P. Invests $1.75 Million in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
27,400 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Bought by Erste Asset Management GmbH - MarketBeat
Revolution Medicines Prices $45 Million Stock, Warrant Offering - Marketscreener.com
Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants - Yahoo Finance
Revolution Medicines Announces Pricing of Upsized $750.0 - GlobeNewswire
Revolution Medicines' SWOT analysis: stock outlook amid RAS inhibitor progress - Investing.com
Revolution’s RAS Plans Move Ahead Despite Investors’ Safety Doubts - News & Insights
HighVista Strategies LLC Boosts Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Cinctive Capital Management LP Purchases 30,430 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines reports progress in cancer drug trials By Investing.com - Investing.com Canada
Revolution Medicines announces $600 million stock offering By Investing.com - Investing.com Canada
Revolution Medicines announces $600 million stock offering - Investing.com India
Revolution Medicines reports progress in cancer drug trials - Investing.com India
Revolution Medicines Launches $600 Million Offering of Common Shares - Marketscreener.com
Revolution Medicines Announces Commencement of Public Offering of Common Stock - The Manila Times
Revolution Medicines Launches $600M Public Stock Offering, Plans $90M Option - StockTitan
Revolution Medicines reports promising trial results for cancer treatments - Investing.com India
Finanzdaten der Revolution Medicines Inc-Aktie (RVMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):